Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13248975 | 0.84 | HTR2A (0.38) | HTR2AHTR2CHTR2BMEN1KMT2A | |
| SCHEMBL13799468 | 0.84 | HTR2A (0.46) | HTR2AHTR2CHTR2BPNMTSRD5A1 | |
| SCHEMBL24990564 | 0.83 | HTR2A (0.40) | HTR2AHTR2CHTR2BPNMTAHR | |
| SCHEMBL24387418 | 0.83 | HTR2A (0.40) | HTR2AHTR2CHTR2BPNMTAHR | |
| SCHEMBL11529130 | 0.81 | KMT2A (0.42) | HTR2AHTR2CHTR2BKMT2APNMT | |
| SCHEMBL23376900 | 0.77 | MEN1 (0.49) | MEN1KMT2AMAPK13DAPK3ROCK2 | |
| Hydrochloric Acid SCHEMBL9518179 | 0.77 | SLC6A4 (0.39) | HTR2AHTR2CHTR2BKMT2APNMT | |
| SCHEMBL11530207 | 0.74 | ADRA2A (0.41) | MEN1KMT2AGAAMAPTMETAP1 | |
| Hydrochloric Acid SCHEMBL9518204 | 0.74 | SLC6A3 (0.44) | HTR2AHTR2CHTR2BPNMTSRD5A1 | |
| SCHEMBL1794485 | 0.73 | PNMT (0.40) | PNMTAHRCMA1PGRMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022090714-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
| CN-114262250-A | Synthetic method of aromatic ring benzyl ortho-position dialkyl | 乐威医药（江苏）股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-10472336-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-20190040023-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-4166131-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, ANTIARTHRITIC AGENT | HEXACHIMIE SOCIETE ANONYME (FR) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | GABRD, GABRA6, GABRB1 | HTR2A 1444/4885HTR2C 1326/4885HTR2B 1129/4885 |
| US-10472336-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | HTR2A 40/4885HTR2C 54/4885HTR2B 281/4885 |
| US-20190040023-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | HTR2A 40/4885HTR2C 54/4885HTR2B 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.